Advertisement

Zolpidem: The Arrested Woman with No Recollection of Events

  • Vijayabharathi Ekambaram
  • Britta Klara OstermeyerEmail author
Chapter

Abstract

Z-drugs, such as zolpidem and zopiclone, have been associated with sleep-related behaviors, parasomnia, abnormal thinking, disinhibition, aggressiveness, mood alterations, and anterograde amnesia. Sleep driving is one of the Z-drug-induced parasomnias reported frequently with zolpidem and often raises diagnostic challenges among clinicians due to its complex presentation and medico legal ramifications. This review focuses on the epidemiology, clinical presentation, psychopharmacology, diagnosis, laboratory tests, and forensic aspects of Z-drug-induced sleep driving. In addition, this review helps practitioners to identify and distinguish Z-drug-induced sleep driving from individuals with history of somnambulism, as this distinction is key for diagnostic clarification in medico legal cases.

Keywords

Sleep driving Sleep walking Drug-induced driving Zolpidem Zopiclone Parasomnia 

References

  1. 1.
    Daley C, McNiel DE, Binder RL. “I did what?” Zolpidem and the courts. J Am Acad Psychiatry Law. 2011;39(4):535–42.PubMedGoogle Scholar
  2. 2.
    Lewis JH, Vine JH. A simple and rapid method for the identification of zolpidem carboxylic acid in urine. J Anal Toxicol. 2007;31(4):195–9.  https://doi.org/10.1093/jat/31.4.195.CrossRefPubMedGoogle Scholar
  3. 3.
    Federal Drug Administration (FDA). NDA 19908 027 FDA approved labeling 4.23.08. 2008. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019908s027lbl.pdf. Accessed 21 Jan 2018.
  4. 4.
    Feinberg I, Maloney T, Campbell IG. Effects of hypnotics on the sleep EEG of healthy young adults: new data and psychopharmacologic implications. J Psychiatr Res. 2000;34:423–38.  https://doi.org/10.1016/s0022-3956(00)00038-8.CrossRefPubMedGoogle Scholar
  5. 5.
    Pressman MR. Sleep driving: sleepwalking variant or misuse of z-drugs? Sleep Med Rev. 2011;15(5):285–92.  https://doi.org/10.1016/j.smrv.2010.12.004.CrossRefPubMedGoogle Scholar
  6. 6.
    Mets MA, Volkerts ER, Olivier B, Verster JC. Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev. 2010;14(4):259–67.  https://doi.org/10.1016/j.smrv.2009.10.008.CrossRefPubMedGoogle Scholar
  7. 7.
    Tsai JH, Yang P, Chen CC, et al. Zolpidem-induced amnesia and somnambulism: rare occurrences? Eur Neuropsychopharmacol. 2009;19:74–6.  https://doi.org/10.1016/j.euroneuro.2008.08.007.CrossRefPubMedGoogle Scholar
  8. 8.
    Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol. 1998;36(3):195–203.  https://doi.org/10.3109/15563659809028939.CrossRefPubMedGoogle Scholar
  9. 9.
    Lange CL. Medication-associated somnambulism. J Am Acad Child Adolesc Psychiatry. 2005;44(3):211–2.  https://doi.org/10.1097/01.chi.0000150618.67559.48.CrossRefPubMedGoogle Scholar
  10. 10.
    Juszczak GR. Desensitization of GABAergic receptors as a mechanism of zolpidem-induced somnambulism. Med Hypotheses. 2011;77(2):230–3.  https://doi.org/10.1016/j.mehy.2011.04.019.CrossRefPubMedGoogle Scholar
  11. 11.
    Sanofi US. Products Ambien package inserts. 2014. Available at http://products.sanofi.us/ambien/ambien.pdf. Accessed 29 Jan 2018.
  12. 12.
    Poceta JS. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7(6):632–8.  https://doi.org/10.5664/jcsm.1468.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Food and Drug Administration (FDA). Questions and answers: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2013. Available at https://www.fda.gov/drugs/drugsafety/ucm334041.htm. Accessed 21 Jan 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Vijayabharathi Ekambaram
    • 1
  • Britta Klara Ostermeyer
    • 1
    Email author
  1. 1.Department of Psychiatry and Behavioral SciencesUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA

Personalised recommendations